Who is sponsoring NCT03106519?

NCT03106519 is sponsored by Catherine Vandepitte, M.D..

What drugs are being tested in NCT03106519?

Interventions in NCT03106519: Liposome bupivacaine + bupivacaine.

What condition does NCT03106519 study?

NCT03106519 studies Dupuytren's Contracture of the Hand (Viking's Disease).

Is NCT03106519 still recruiting?

NCT03106519 is currently completed. Last updated 10 September 2020.

Last reviewed 2020-09-10 · How we verify

NCT03106519

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Liposome Bupivacaine for WRIST Blocks

Completed Phase 2 Last updated 10 September 2020

What this trial tests

Phase 2 trial testing Liposome bupivacaine + bupivacaine in Dupuytren's Contracture of the Hand (Viking's Disease) in 32 participants. Completed in 31 October 2017.

Timeline

2 January 2017

Primary endpoint
28 June 2017

31 October 2017

Quick facts

Lead sponsor	Catherine Vandepitte, M.D.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	32
Start date	2 January 2017
Primary completion	28 June 2017
Estimated completion	31 October 2017
Sites	1 location across Belgium

Drugs / interventions tested

Liposome bupivacaine + bupivacaine — full drug profile →

Conditions studied

Dupuytren's Contracture of the Hand (Viking's Disease) — all drugs for Dupuytren's Contracture of the Hand (Viking's Disease) →

Sponsor

Catherine Vandepitte, M.D. — full company profile →

Who can join

Adults 18 to 85, any sex, with Dupuytren's Contracture of the Hand (Viking's Disease). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Treatment of Dupuytren's contracture requires multiple injections into the palm of the hand to weaken the cords, followed by rupture of the strands 2 days later. Anesthesia is required for both phases of treatment. It is hypothesized that extended-release liposome bupivacaine prolongs nerve blockade of the wrist allowing patients to undergo this 2-part regimen with less pain.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of Bupivacaine Liposome Injectable Suspension on Sensory Blockade and Analgesia for Dupuytren Contracture Release.
Vandepitte CF, Van Boxstael S, Duerinckx JF, Leunen I, et al · · 2019 · cited 7× · PMID 37470047 · DOI 10.1016/j.jhsg.2019.09.008

Verify or expand the search:

Other Catherine Vandepitte, M.D. trials

Trials by the same sponsor.

NCT03106545 — Liposome Bupivacaine for ANKLE Blocks · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03106519 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Catherine Vandepitte, M.D.
Last refreshed: 10 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03106519.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing